Eli Lilly’s stock soars as Mounjaro, Zepbound sales lead to a big profit beat

By / / Finance / 1 minute of reading



im 656195
Eli Lilly’s stock was headed for its best day in a year on Thursday, after the drugmaker reported second-quarter earnings that rose well above forecasts, amid strength in sales of its diabetes and obesity treatments, Mounjaro and Zepbound.



Source link

About The Author

Avatar of Jana Carter
Jana Carter is a news writer and editor at Pax Press Agency. She's also a tech enthusiast, an avid reader, and an artist in her free time. She loves to write about everything from sports to art to politics—and she always strives to make her writing fun, accessible, and informative.

Start typing and press enter to search

Scroll to Top